Capvest acquires NextPharma from Sun European Partners

28 June 2017, London, UK: Funds advised by CapVest Partners LLP (“CapVest”) have signed a definitive agreement to acquire NextPharma, a leading pharmaceutical contract development and manufacturing organisation (CDMO), from an affiliate of Sun European Partners, LLP (“Sun European Partners” or “Sun”). The proposed transaction is subject to customary regulatory approvals.

NextPharma is a market leader within the European pharmaceutical CDMO space, serving a global bluechip customer base, including seven of the top ten pharma companies. The company offers a broad range of specialised product types and therapeutic areas across multiple attractive niches. NextPharma has over 1,000 employees and operations in Germany, France, Switzerland and Austria.

CapVest is a leading London-based private equity firm and is committed to further enhancing NextPharma’s focus on patient care through its production and supply of the highest quality medicines from its state-of-the-art European production facilities.

Commenting on the deal, Peter Burema, CEO of NextPharma said: “Over the years, Sun and NextPharma have enjoyed an enormously successful partnership; bringing about substantial growth and development to the company and delivering a superior service to our customers around the world. The strategies implemented have put NextPharma in a much stronger position and management look forward to partnering with CapVest in building on our core values of quality, speed and service, and further expanding our customer offering.”

Christopher Campbell, Partner, CapVest added: “NextPharma is an excellent business with a leadership position in a growing market and we look forward to supporting management on the next exciting phase in the company’s journey.”